Summary & Overview

CPT 0603U: SLL Comprehensive Drug Analysis, Urine LC–MS/MS Presumptive Screen

CPT code 0603U designates a Proprietary Laboratory Analyses (PLA) test for the SLL Comprehensive Drug Analysis from Soft Landing Labs®, a urine-based presumptive screen for 77 drugs and metabolites using liquid chromatography–tandem mass spectrometry (LC–MS/MS). As a PLA code, 0603U links a single, manufacturer- or lab-specific assay to a unique billing identifier, supporting clearer tracking and reporting of novel or proprietary diagnostics nationwide. This matters for payers, laboratories, and clinicians because PLA codes influence claims processing, pricing transparency, and the ability to monitor utilization of specialized tests.

Key payers in scope for national coverage comparisons include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for the assay, information on typical site of service and service type, and a summary of which payers are considered in coverage comparisons. The publication will also cover benchmarks and policy-related considerations relevant to PLA-coded tests, implications for coding and billing workflows, and where to look for updates on coding guidance and payer policy.

Data not available in the input: specific payer coverage policies, common modifiers, associated taxonomies, linked ICD-10 diagnoses, related codes, and service line details.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicare0603UCPTProprietary Laboratory AnalysesPLAurine drug screenLC-MS/MSclinical laboratorytoxicologydrug testing

Billing Code Overview

CPT code 0603U is a Proprietary Laboratory Analyses (PLA) code that applies to a single, unique laboratory test: the SLL Comprehensive Drug Analysis from Soft Landing Labs®. This urine-based test uses liquid chromatography with tandem mass spectrometry (LC–MS/MS) to perform presumptive screening for 77 drugs and metabolites and reports results as positive or negative.

Service type: Laboratory — urine drug screening using LC–MS/MS (presumptive)

Typical site of service: Clinical laboratory

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A 34-year-old patient enrolled in an outpatient substance use disorder treatment program provides a urine specimen at the clinic as part of routine monitoring. The clinician orders a comprehensive urine drug screen to presumptively detect recent use of a broad panel of substances to guide counseling and care. The specimen is sent to Soft Landing Labs® for the SLL Comprehensive Drug Analysis. The laboratory performs liquid chromatography with tandem mass spectrometry (LC–MS/MS) to screen for 77 drugs and metabolites and reports each analyte as positive or negative. Results are returned to the ordering clinician and integrated into the patient’s electronic health record to inform clinical decision-making, including medication management, treatment planning, and compliance monitoring.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when reporting only the professional interpretation component if separated from the laboratory technical service (rare for PLA tests but applicable if a different entity bills interpretation).
`TC`	Technical component	Use when reporting only the laboratory technical component (instrumentation, processing) and the professional component is billed separately.
`90`	Reference (outside) laboratory	Use when the specimen is sent to an outside reference laboratory for testing and billing needs to indicate external lab performance.
`91`	Repeat clinical diagnostic laboratory test	Use when the same test is repeated on the same day to confirm unexpected or critical results.
`59`	Distinct procedural service	Use when reporting this test on the same day as another service where reporting as distinct is required and clinical circumstances support separate services.
`24`	Unrelated evaluation and management service by the same physician during a postoperative period	Use when an unrelated E/M visit occurs on the same day as specimen collection for this test during a global period.
`25`	Significant, separately identifiable E/M service by the same physician on the same day	Use when a significant E/M is performed the same day as specimen collection and must be reported separately.
`52`	Reduced services	Use when the laboratory test is partially reduced or not completed as originally described and partial payment reporting is required.
`53`	Discontinued procedure	Use when testing was started but discontinued due to patient factors or specimen issues before completion.
`22`	Increased procedural services	Use when the test required substantially greater resources or complexity than typical (document rationale).
`QW`	CLIA waived test	Not applicable to LC–MS/MS PLA but listed for completeness; do not use for this test.
`GQ`	Telehealth originating site (technical modifiers for other contexts)	Not typically applicable to laboratory testing; omit unless specific payer requires.
`KX`	Requirements specified in coverage determination have been met	Use when payer requires attestation of medical necessity criteria met for the test and documentation supports it.

Taxonomy Code	Specialty	Notes
`2084P0800X`	Clinical Lab Physician	Physicians overseeing clinical laboratory testing and interpretation.
`207Q00000X`	Pathology & Clinical Pathology	Pathologists responsible for laboratory oversight and test validation.
`261QM0800X`	Clinical Laboratory Technologist	Laboratory professionals performing LC–MS/MS testing and analytic procedures.
`174400000X`	Addiction Medicine	Clinicians ordering comprehensive drug testing for monitoring treatment adherence.
`208D00000X`	Family Medicine	Primary care providers ordering urine drug screens in office-based substance use monitoring.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`F11.10`	Opioid abuse, uncomplicated	Common indication for comprehensive urine drug screening to monitor for opioid use and treatment adherence.
`F11.20`	Opioid dependence, uncomplicated	Used when monitoring patients in medication-assisted treatment for opioid dependence.
`F12.10`	Cannabis abuse, uncomplicated	Included when checking for recent cannabis use in substance use evaluations.
`F19.20`	Other psychoactive substance dependence, uncomplicated	Broad category supporting multi-drug screening when polysubstance use is suspected.
`Z71.51`	Screening for substance use and abuse	Preventive or screening encounter warranting comprehensive drug testing in at-risk populations.
`R78.89`	Other abnormal findings of urine chemistry	Used when abnormal urine findings prompt expanded drug testing.
`Z20.828`	Contact with and (suspected) exposure to other viral communicable diseases	Not directly related but occasionally present on records; include only if clinically relevant.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`0603U`	SLL Comprehensive Drug Analysis; urine LC–MS/MS presumptive screen for 77 drugs and metabolites (PLA)	This is the primary PLA test performed by Soft Landing Labs® to screen urine for 77 drugs and metabolites; report when this exact proprietary test is performed.
`80305`	Drug test(s), presumptive, any number of drug classes; urine, non-quantitative, multiple drug classes by instrumented chemistry analyzers	May be ordered in settings where non-mass-spectrometry presumptive multi-drug screening is used prior to or instead of LC–MS/MS confirmatory testing.
`80307`	Drug confirmation, any assay; e.g., chromatographic technique, each drug class analyzed (e.g., gas or liquid chromatography, mass spectrometry)	Used when confirmatory quantitative or qualitative testing by GC/MS or LC–MS/MS is performed on specific positive findings from an initial screen.
`81025`	Urine pregnancy test, by dipstick or tablet reagent for pregnancy, with instrumented reading	Often performed alongside urine drug screening in reproductive-aged patients to inform clinical management.
`99000`	Handling and/or conveyance of specimen for transfer from/to outside laboratory	Used when there is a billable charge for specimen handling or transfer to an external reference laboratory in certain payer arrangements.

Beta

OpenPayer Beta

Summary & Overview

CPT 0603U: SLL Comprehensive Drug Analysis, Urine LC–MS/MS Presumptive Screen

Data not available in the input: specific payer coverage policies, common modifiers, associated taxonomies, linked ICD-10 diagnoses, related codes, and service line details.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicare0603UCPTProprietary Laboratory AnalysesPLAurine drug screenLC-MS/MSclinical laboratorytoxicologydrug testing

Billing Code Overview

Service type: Laboratory — urine drug screening using LC–MS/MS (presumptive)

Typical site of service: Clinical laboratory

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when reporting only the professional interpretation component if separated from the laboratory technical service (rare for PLA tests but applicable if a different entity bills interpretation).
`TC`	Technical component	Use when reporting only the laboratory technical component (instrumentation, processing) and the professional component is billed separately.
`90`	Reference (outside) laboratory	Use when the specimen is sent to an outside reference laboratory for testing and billing needs to indicate external lab performance.
`91`	Repeat clinical diagnostic laboratory test	Use when the same test is repeated on the same day to confirm unexpected or critical results.
`59`	Distinct procedural service	Use when reporting this test on the same day as another service where reporting as distinct is required and clinical circumstances support separate services.
`24`	Unrelated evaluation and management service by the same physician during a postoperative period	Use when an unrelated E/M visit occurs on the same day as specimen collection for this test during a global period.
`25`	Significant, separately identifiable E/M service by the same physician on the same day	Use when a significant E/M is performed the same day as specimen collection and must be reported separately.
`52`	Reduced services	Use when the laboratory test is partially reduced or not completed as originally described and partial payment reporting is required.
`53`	Discontinued procedure	Use when testing was started but discontinued due to patient factors or specimen issues before completion.
`22`	Increased procedural services	Use when the test required substantially greater resources or complexity than typical (document rationale).
`QW`	CLIA waived test	Not applicable to LC–MS/MS PLA but listed for completeness; do not use for this test.
`GQ`	Telehealth originating site (technical modifiers for other contexts)	Not typically applicable to laboratory testing; omit unless specific payer requires.
`KX`	Requirements specified in coverage determination have been met	Use when payer requires attestation of medical necessity criteria met for the test and documentation supports it.

Taxonomy Code	Specialty	Notes
`2084P0800X`	Clinical Lab Physician	Physicians overseeing clinical laboratory testing and interpretation.
`207Q00000X`	Pathology & Clinical Pathology	Pathologists responsible for laboratory oversight and test validation.
`261QM0800X`	Clinical Laboratory Technologist	Laboratory professionals performing LC–MS/MS testing and analytic procedures.
`174400000X`	Addiction Medicine	Clinicians ordering comprehensive drug testing for monitoring treatment adherence.
`208D00000X`	Family Medicine	Primary care providers ordering urine drug screens in office-based substance use monitoring.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`F11.10`	Opioid abuse, uncomplicated	Common indication for comprehensive urine drug screening to monitor for opioid use and treatment adherence.
`F11.20`	Opioid dependence, uncomplicated	Used when monitoring patients in medication-assisted treatment for opioid dependence.
`F12.10`	Cannabis abuse, uncomplicated	Included when checking for recent cannabis use in substance use evaluations.
`F19.20`	Other psychoactive substance dependence, uncomplicated	Broad category supporting multi-drug screening when polysubstance use is suspected.
`Z71.51`	Screening for substance use and abuse	Preventive or screening encounter warranting comprehensive drug testing in at-risk populations.
`R78.89`	Other abnormal findings of urine chemistry	Used when abnormal urine findings prompt expanded drug testing.
`Z20.828`	Contact with and (suspected) exposure to other viral communicable diseases	Not directly related but occasionally present on records; include only if clinically relevant.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`0603U`	SLL Comprehensive Drug Analysis; urine LC–MS/MS presumptive screen for 77 drugs and metabolites (PLA)	This is the primary PLA test performed by Soft Landing Labs® to screen urine for 77 drugs and metabolites; report when this exact proprietary test is performed.
`80305`	Drug test(s), presumptive, any number of drug classes; urine, non-quantitative, multiple drug classes by instrumented chemistry analyzers	May be ordered in settings where non-mass-spectrometry presumptive multi-drug screening is used prior to or instead of LC–MS/MS confirmatory testing.
`80307`	Drug confirmation, any assay; e.g., chromatographic technique, each drug class analyzed (e.g., gas or liquid chromatography, mass spectrometry)	Used when confirmatory quantitative or qualitative testing by GC/MS or LC–MS/MS is performed on specific positive findings from an initial screen.
`81025`	Urine pregnancy test, by dipstick or tablet reagent for pregnancy, with instrumented reading	Often performed alongside urine drug screening in reproductive-aged patients to inform clinical management.
`99000`	Handling and/or conveyance of specimen for transfer from/to outside laboratory	Used when there is a billable charge for specimen handling or transfer to an external reference laboratory in certain payer arrangements.